Conversion Surgery for Stage IV Gastric Cancer After Third-line Immunotherapy: a Case Report

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Dec 23

PMID 39711962

Authors

Sevindzh F Evdokimova

Anna L Kornietskaya

Larisa V Bolotina

Iliya V Kolobayev

Alexander A Fedenko

Andrey D Kaprin

Affiliations

Soon will be listed here.

Abstract

The 5-year overall survival rate for stage IV gastric cancer is lower than 10%, despite the development of systemic therapy. Conversion surgery has shown to improve survival outcomes in patients with durable clinical response on chemotherapy. We report a clinical case of a patient, who underwent conversion surgery after pembrolizumab in the third-line setting for stage IV gastric cancer. The patient did not have recurrence for 22 months after conversion surgery.

References

Thomassen I, van Gestel Y, van Ramshorst B, Luyer M, Bosscha K, Nienhuijs S . Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2013; 134(3):622-8. DOI: 10.1002/ijc.28373. View

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

Kim S . The result of conversion surgery in gastric cancer patients with peritoneal seeding. J Gastric Cancer. 2015; 14(4):266-70. PMC: 4286906. DOI: 10.5230/jgc.2014.14.4.266. View

Fukuchi M, Ishiguro T, Ogata K, Suzuki O, Kumagai Y, Ishibashi K . Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer. Ann Surg Oncol. 2015; 22(11):3618-24. DOI: 10.1245/s10434-015-4422-6. View

Le D, Ott P, Korytowsky B, Le H, Le T, Zhang Y . Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Colorectal Cancer. 2019; 19(1):32-38.e3. DOI: 10.1016/j.clcc.2019.09.001. View

Shin M, Choi M, Kim S, Kang W, Sohn T, An J . The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy. Biomedicines. 2023; 11(11). PMC: 10669208. DOI: 10.3390/biomedicines11113097. View

Wang T, Wang N, Ren H, Zhou H, Zhou A, Jin J . Long-term Results of Conversion Therapy for Initially Unresectable Gastric Cancer: Analysis of 122 Patients at the National Cancer Center in China. J Cancer. 2019; 10(24):5975-5985. PMC: 6856572. DOI: 10.7150/jca.35527. View

Ni L, Chen S, Liu J, Li H, Zhao H, Zheng C . GPR176 Is a Biomarker for Predicting Prognosis and Immune Infiltration in Stomach Adenocarcinoma. Mediators Inflamm. 2023; 2023:7123568. PMC: 10132901. DOI: 10.1155/2023/7123568. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y . The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2017; 21(2):315-323. PMC: 5846815. DOI: 10.1007/s10120-017-0738-1. View

11.

Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T . Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie.... J Clin Oncol. 2014; 32(31):3520-6. DOI: 10.1200/JCO.2013.54.1011. View

12.

Ito S, Oki E, Nakashima Y, Ando K, Hiyoshi Y, Ohgaki K . Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. Anticancer Res. 2015; 35(1):401-6. View

13.

Enzinger P, Burtness B, Niedzwiecki D, Ye X, Douglas K, Ilson D . CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016; 34(23):2736-42. PMC: 5019745. DOI: 10.1200/JCO.2015.65.5092. View

14.

Hu H, Tsai H, Ku H, Lo S, Shan Y, Chang H . Survival outcomes of management in metastatic gastric adenocarcinoma patients. Sci Rep. 2021; 11(1):23142. PMC: 8633380. DOI: 10.1038/s41598-021-02391-z. View

15.

Zurleni T, Gjoni E, Altomare M, Rausei S . Conversion surgery for gastric cancer patients: A review. World J Gastrointest Oncol. 2018; 10(11):398-409. PMC: 6247102. DOI: 10.4251/wjgo.v10.i11.398. View

16.

Wagner A, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J . Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; (3):CD004064. DOI: 10.1002/14651858.CD004064.pub3. View

17.

Fukuda K, Arigami T, Tokuda K, Yanagita S, Matsushita D, Kawasaki Y . Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report. Surg Case Rep. 2022; 8(1):58. PMC: 8975963. DOI: 10.1186/s40792-022-01412-x. View

18.

Solaini L, Ministrini S, Bencivenga M, DIgnazio A, Marino E, Cipollari C . Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study. Gastric Cancer. 2019; 22(6):1285-1293. DOI: 10.1007/s10120-019-00968-2. View

19.

Chan W, Lam K, So T, Lee V, Kwong L . Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. Ther Adv Med Oncol. 2019; 11:1758835919859990. PMC: 6600493. DOI: 10.1177/1758835919859990. View

20.

Luo H, Xu R, Wang F, Qiu M, Li Y, Li F . Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy. 2010; 56(2):94-100. DOI: 10.1159/000305256. View